echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > World J Urol: Evaluation of the effect of gemcitabine-carboplatin and gemcitabine-cisplatin in the treatment of muscle-invasive bladder cancer

    World J Urol: Evaluation of the effect of gemcitabine-carboplatin and gemcitabine-cisplatin in the treatment of muscle-invasive bladder cancer

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cisplatin chemotherapy is recommended for patients with muscular-invasive bladder cancer (MIBC), followed by radical cystectomy (RC


    Recently, researchers from the Netherlands published an article in World J Ulol comparing the clinical outcomes of preoperative gem-carbo and gem-carbo after 3 cycles of ≥ treatment


    The study included 1865 patients


    A total of 747 patients treated with gem-carbo (n=147) and gem-cis (n=600) were included in the


    Comparison of overall survival between the two treatment groups

    In summary, some MIBC patients who do not meet the conditions for cisplatin use obtain pCR in gem-carbo treatment, and if the patient can undergo ≥ 3 cycles and receive RC treatment, their survival outcomes may be comparable


    Original Source:

    Sarah M H Einerhand , Anna J Black , Homayoun Zargar et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.